LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), an immunotherapy company developing innovative treatments for patients with cancer, announced that in connection with its acquisition of XOMA Corporation’s antibody manufacturing pilot plant it granted stock options and restricted stock units to 28 new employees covering a total of 535,824 shares of Agenus common stock. The awards were approved by Agenus’ compensation committee and granted as inducements material to the new employees entering into employment with Agenus, as permitted under NASDAQ Listing Rule 5635(c)(4).
